Seroquel Tablets 25mg, 100mg, 200mg and 300mg

  • Name:

    Seroquel Tablets 25mg, 100mg, 200mg and 300mg

  • Company:
    info
  • Active Ingredients:

    Quetiapine fumarate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 09/05/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 23/1/2019

Click on this link to Download PDF directly

AstraZeneca Pharmaceuticals (Ireland) DAC

AstraZeneca Pharmaceuticals (Ireland) DAC

Company Products

Medicine NameActive Ingredients
Medicine Name Alvesco 160 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Alvesco 80 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Arimidex Active Ingredients Anastrozole
Medicine Name Atacand 8mg 16mg Tablets Active Ingredients Candesartan Cilexetil
Medicine Name Atacand Plus 16/12.5mg Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Medicine Name Bricanyl Turbohaler Active Ingredients Terbutaline sulfate
Medicine Name Brilique 60 mg film-coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg film coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg Orodispersible Tablets Active Ingredients Ticagrelor
Medicine Name Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen Active Ingredients Exenatide
Medicine Name Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen Active Ingredients Exenatide
Medicine Name Casodex 50mg Tablets Active Ingredients Bicalutamide
Medicine Name Crestor 5 mg, 10 mg, 20 mg and 40 mg Tablets Active Ingredients Rosuvastatin Calcium
Medicine Name Daxas 250 mcg Film-Coated Tablets Active Ingredients roflumilast
Medicine Name Daxas 500 mcg Film-coated Tablets Active Ingredients roflumilast
Medicine Name Fasenra 30 mg solution for injection in pre filled syringe Active Ingredients Benralizumab
Medicine Name Faslodex Active Ingredients Fulvestrant
Medicine Name Forxiga 10 mg Film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name Forxiga 5 mg film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name IMFINZI 50 mg/mL concentrate for solution for infusion Active Ingredients durvalumab
Medicine Name IRESSA 250 mg film-coated tablets Active Ingredients gefitinib
Medicine Name Komboglyze 2.5mg-1000mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Komboglyze 2.5mg-850mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Losec MUPS 10mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Losec MUPS 20mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
1 - 0 of 52 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 9 May 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 23 January 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 23 January 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 10 October 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 10 October 2018 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8- editiorial changes to the ADR table 1.

Section 4.8- Drug rash with eosinophilia and systemic symptoms (DRESS) added as 'Not known' undesirable effect under SOC Skin and subcutaneous tissue disorders.

Section 4.8 - 'Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with quetiapine treatment.' added to section 4.8.

Section 10 - change to the date of revision to 4th October 2018.

Updated on 29 May 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 29 May 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to further information section

Updated on 3 January 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 3 January 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 28 September 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections 2, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2, 5.3, 6.1, 9 - Change to improve clarity and readability (in line with QRD template)

Section 4.4 – Addition of potential for misuse and abuse particularly by patients with a history of drug or alcohol abuse.

Section 9 – Addition of the Renewal Date

Section 10 – Date of last update

Updated on 28 September 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 September 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 5 October 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4: addition of information on sleep apnoea syndrome

Section 4.4: addition of information on anti-cholingeric (muscarinic) effects

Section 4.5: addition of information on patients receiving other medications that have anti-cholinergic effects

Section 4.8: editorial change

Section 4.9: addition of anti-cholingeric effects as a symptom of overdose

Section 5.1: addition of text regarding quetiapine having low or no affinity for muscarinic receptors while norquetiapine does which may explain anti-cholingeric (muscarinic) effects

Section 5.1: Paediatric population: clinical safety: amendment of rates weight gain of baseline body weight vs placebo:  in the bipolar depression trial from 12.5% vs 6% to 13.7% vs 6.8%

Section 10: updated date of revision

Updated on 1 October 2015 PIL

Reasons for updating

  • Correction of spelling/typing errors
  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to date of revision

Updated on 9 September 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2 – editorial changes

Section 4.2 – editorial changes

Section 4.3 – editorial changes

Section 4.4 – editorial changes

Section 4.4 –removal of text that ‘data do not establish a causal relationship between quetiapine treatment and death in elderly patients with dementia.’

Section 4.8 – ADR table - ‘neutropenia’ side effect moved from ‘not known’ frequency to ‘uncommon’

Section 4.8 – ADR table – ‘exacerbation of pre-existing diabetes’ side effect from ‘very rare’ to ‘uncommon’

Section 4.8 – footnotes: editorial changes

Section 4.9 – editorial changes

Section 5.1 – editorial changes

Section 10 – updated date of revision

Updated on 7 September 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Correction of spelling/typing errors

Updated on 1 July 2015 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 4 December 2014 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

section 1 – editorial changes

section 2- editorial changes

section 3 –editorial changes

section 4.1 – editorial changes

section 4.2 – editorial changes

section 4.4 – editorial changes, addition of text for severe neutropenia and agranulocytosis, cardiomyopathy and myocarditis. More information added to constipiation and intestinal obstruction section

section 4.5 – editorial changes

section 4.6 – amendment of text on pregnancy, breast-feeding and fertility

section 4.8 – amendment of ADR  table. Paediatric ADR table, editorial changes

section 4.8 – amendment of HPRA address (ADR statement)

section 4.9 - editorial changes

section 5.1 – amendment of mechanism of action text regarding norquetiapine

section 5.2 – editorial changes

section 5.3 – amendment in text re embrofoetal toxicity study

section 6.1 - editorial changes

section 6.5 – amendment of pack in table

section 10 – updated date of revision

Updated on 28 November 2014 PIL

Reasons for updating

  • Change to storage instructions
  • Change to side-effects
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.
  • Improved electronic presentation
  • Change to warnings or special precautions for use

Updated on 28 March 2014 SmPC

Reasons for updating

  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Section 4.9 Addition of the following words which were accidently rejected instead of accepted during the approval management of CNS 14 0003.

Updated on 18 March 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Section 4.1 & 4.2

Administrative changes: amended line spacing and addition of hard spaces.


- Section 4.4

Addition of irritability to the safety profile with a different implication for children and adolescents

Addition of agranulocytosis and management thereof

Addition of constipation and intestinal obstruction as a risk factor

Administrative changes to formatting and layout

 

- Section 4.8

Unknown updated to Not known

Addtional and unnecessary spaces removed

Addition of Intestinal obstruction/ Ileus and urinary retention to table and addition of neutropenia to table footnotes

Changed transaminases to aminotransferase

Addition of table 2 heading ADRs in children and adolescents higher than or not identified in adults

Moved elevations in prolactin to endocrine disorders

Moved increases in blood pressure to vascular disorders

Added extraprimidal symptoms as very common

Addition of adverse event reporting instructions

 

- Section 4.9

Addition of a heading for symptoms and simplification of symptoms

Removal of quantities of quetiapine resulting in a fatal outcome or survival following an overdose

Addition of published literature information for management of overdose

 

- Section 5.1 and 5.2

Administrative changes to improve text layout and readability

 

- Section 5.3

Addition of embryofoetal and fertility data


-Section 10
Updated date of revision

Updated on 13 March 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Addition of information on reporting a side effect.

Updated on 2 September 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 – Paediatrics

Section 4.5 – Lithium PAC

Section 4.8 – Paediatrics and CSP

Section 5.1 - Lithium PAC and Paediatrics
Section 10 - updated date of revision

Updated on 28 August 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 25 March 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change of distributor details

Updated on 12 March 2013 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

editorial changes
section 10 - updated date of revision

Updated on 7 March 2013 PIL

Reasons for updating

  • Change to date of revision
  • Improved electronic presentation

Updated on 10 May 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

 

Revised wording of Metabolic Risk warning, addition of Pancreatitis warning and minor editorial change to replace Seroquel with quetiapine.


Section 4.6

 

Revised wording concerning excretion into breast milk and addition of information relating to risks associated with exposure of neonates to antipsychotics.

 

Section 4.8

 

Adverse Events table revised based on approved Core Safety Profile.

 

Section 4.9

 

Minor editorial change to replace Seroquel with quetiapine.

 

Section 10

 

Date of revision updated to 26th April 2012.

 

Updated on 2 May 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 2 January 2012 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 3

 

Administrative correction to tablet appearance (for immediate release only).

 

Section 4.1

 

Administrative change to indications (for immediate release only).

 

Section 4.2

 

Clarification different dosing required for different indications.

 

Section 4.4

 

Clarification the safety profile should be considered in accordance with dose and indication.

Administrative changes to replace Seroquel with quetiapine.

Expanded suicide risk warning.

Moved text on Extrapyramidal symptoms and Tardive Dyskinesia.

Added dizziness to heading with somnolence and added clarification on the risk to elderly.

Added information on incidence of seizures.

 

Section 4.5

 

Information on interaction with valproate and quetiapine.

 

Section 4.8

 

Addition of new undesirable effects in line with current information.

Moved some text to clinical safety section 5.1.

 

Section 4.9

 

Addition of symptoms and management of overdose.

 

Section 5.1

 

Addition of text to clinical safety from 4.8.

 

Section 5.2

 

Addition of text to pharmacokinetic properties.

 

Section 10

 

Date of revision changed to 19th December 2011

 

Updated on 22 December 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to appearance of the medicine

Updated on 8 June 2011 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 21 March 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

New sub heading ‘weight’

Weight

Weight gain has been reported in patients who have been treated with quetiapine, and should be

monitored and managed as clinically appropriate as in accordance with utilised antipsychotic guidelines (See Sections 4.8 and 5.1).

 

Section 4.4

Change of text under sub heading ‘Hyperglycaemia’

 

Section 4.4

Additional text under the sub heading ‘Cardiovascular’:

A slower titration regimen could be considered in patients with underlying cardiovascular disease.

 

Section 4.5

Additional text at end of section:

There have been reports of false positive results in enzyme immunoassays for methadone and tricyclic antidepressants in patients who have taken quetiapine. Confirmation of questionable immunoassay screening results by an appropriate chromatographic technique is recommended.

 

Section 4.8

Additional side effects:

Under Endocrine disorders

Very rare:              Inappropriate antidiuretic hormone secretion

 

Under Metabolism and nutritional disorders

Common:               Increased appetite

Uncommon:          Hyponatraemia20

 

Under Vascular disorders

Rare:                      Venous thromboembolism 1

(this has been moved from the table under ‘Investigations’)

 

Under Musculoskeletal and connective tissue disorders

Very rare:          Rhabdomyolysis

 

Under Reproductive system and breast disorders

Uncommon:          Sexual dysfunction

 

Rare:                      breast swelling, menstrual disorder

 

 

Under Investigation

Very common      Decreased haemoglobin 21

 

Under table there is additional footnotes:

(20) - Shift from >132 mmol/L to ≤132 mmol/L on at least one occasion.

 

(21) Decreased haemoglobin to ≤13 g/dL (8.07 mmol/L) males, ≤12 g/dL (7.45 mmol/L) females on at least one occasion occurred in 11% of quetiapine patients in all trials including open label extensions. For these patients, the mean maximum decrease in haemoglobin at any time was –1.50 g/dL.

 

Section 4.9

Change of text in penultimate paragraph of section.

 

Section 5.1

Additional  information regarding Cataracts/lens opacities

Cataracts/lens opacities

In a clinical trial to evaluate the cataractogenic potential of Seroquel (200‑800 mg/day) versus risperidone (2‑8 mg) in patients with schizophrenia or schizoaffective disorder, the percentage of patients with increased lens opacity grade was not higher in Seroquel (4%) compared with risperidone (10%), for patients with at least 21 months of exposure.

 

Section 5.3

Reference to Cataracts/lens opacities in section 5.1

 

Section 10

Revision date of text: 24th February 2011

Updated on 18 March 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 6 September 2010 PIL

Reasons for updating

  • Change of manufacturer

Updated on 5 August 2010 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 10 March 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 10 March 2010 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

Additional text penultimate paragraph

 

Venous Thromboembolism (VTE)

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Seroquel and preventive measures undertaken.

 

Section 4.8

In the first table under the heading ‘Nervous system disorders’

Common:       addition of ‘Dysarthria’

Uncommon:   deletion of ‘Dysarthria’

 

In the first table under the heading ‘Investigations’

Rare:  addition of ‘Venous thromboembolism’

 

Section 10

New revision date of text: 19th February 2010

Updated on 26 February 2010 PIL

Reasons for updating

  • Change to side-effects
  • Change to warnings or special precautions for use

Updated on 10 February 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to include paediatric information

 

Section 4.2

Children and Adolescents:

Seroquel is not recommended for use in children and adolescents below 18 years of age, due to a lack of data to support use in this age group. The available evidence from placebo-controlled clinical trials is presented in sections 4.4, 4.8, 5.1 and 5.2.

 

 

Section 4.4

Additional new text regarding children and adolescents

Children and adolescents (10 to 17 years of age)

Seroquel is not recommended for use in children and adolescents below 18 years of age, due to a lack of data to support use in this age group. Clinical trials have shown that in addition to the known safety profile identified in adults (see section 4.8), certain adverse events occurred at a higher frequency in children and adolescents compared to adults (increased appetite, elevations in serum prolactin, and extrapyramidal symptoms) and one was identified that has not been previously seen in adult studies (increases in blood pressure). Changes in thyroid function tests have also been observed in children and adolescents.

 

Furthermore, the long-term safety implications of treatment on growth and maturation have not been studied beyond 26 weeks. Long-term implications for cognitive and behavioural development are not known.

 

In placebo-controlled clinical trials with children and adolescent patients, quetiapine was associated with an increased incidence of extrapyramidal symptoms (EPS) compared to placebo in patients treated for schizophrenia and bipolar mania (see section 4.8).

 

In the same section under the heading Extrapyramidal symptoms:

The text includes the words ‘adult patients’

In placebo controlled clinical trials of adult patients quetiapine……

 

Section 4.8

Additional text in the footnotes 11 and 12 to include information on patients less than 18 years of age.

 

Additionally, new text and frequencies table  regarding Children and adolescents (10 to 17 years of age)

 

Section 5.1

New additional text regarding Children and adolescents (10 to 17 years of age)

 

Section 5.2

New additional text regarding Children and adolescents (10 to 17 years of age)

 

Section 10

Revision date of text: 29 January 2010

Updated on 15 January 2010 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 3

Includes description of shape and engraving

 

Section 4.1

Includes information regarding recurrence prevention.

 

Section 4.2

Change of text under the heading “For the treatment of depressive episodes in bipolar disorder”

And new text under the heading “For preventing recurrence in bipolar disorder”:

For preventing recurrence of manic, mixed or depressive episodes in bipolar disorder, patients who have responded to quetiapine for acute treatment of bipolar disorder should continue therapy at the same dose. The dose may be adjusted depending on clinical response and tolerability of the individual patient, within the range of 300 to 800 mg/day administered twice daily. It is important that the lowest effective dose is used for maintenance therapy.

 

Section 5.1

New additional text:

In one long-term study (up to 2 years treatment) evaluating recurrence prevention in patients with manic, depressed or mixed mood episodes quetiapine was superior to placebo in increasing the time to recurrence of any mood event (manic, mixed or depressed), in patients with bipolar I disorder. The number of patients with a mood event was 91 (22.5%) in the quetiapine group, 208 (51.5%) in the placebo group and 95 (26.1%) in the lithium treatment groups respectively. In patients who responded to quetiapine, when comparing continued treatment with quetiapine to switching to lithium, the results indicated that a switch to lithium treatment does not appear to be associated with an increased time to recurrence of a mood event.

 

Section 6.1

Text of Core and Coating is now listed and table format removed.

 

Section 9

Renewal date from 8th September 2009

 

Section 10

Revision date of text: 22nd December 2009

Updated on 7 January 2010 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 10 September 2009 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.5

Change of last sentence in paragraph 2 to:

'It is also not recommended to consume grapefruit juice while on quetiapine therapy.'

Section 4.8

Addition of common side effect:

'Endocrine disorders: Hyperprolactinaemia'

Addition of common side effect:

'Metabolism and nutritional disorders: Increased appetite'

Addition of rare side effect:

'Reproductive system and breast disorders: Galactorrhoea'

Addition of common side effect:

'General disorders and administration site conditions: Irritability'

Change of side effect from common to very common:

'Investigations: Weight gain'

New information added to point (9) under table:

'(9) Based on >7% increase in body weight from baseline. Occurs predominantly during the early weeks of treatment in adults.'

New points under table:

(16) Prolactin levels (patients >18 years of age): >20 μg/L (>869.56 pmol/L) males; >30 μg/L (>1304.34 pmol/L) females at any time.
(17) May lead to falls.

Section 5.1

Deletion of paragraph under Clinical Efficacy:

'Unlike many other antipsychotics, quetiapine does not produce sustained elevations in prolactin, which is considered a feature of atypical agents. In a multiple fixed-dose clinical trial, there were no differences in prolactin levels at study completion, for quetiapine across the recommended dose range, and placebo.'

Section 10

Change of date to:

'17th July 2009'

Updated on 9 September 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 8 May 2009 PIL

Reasons for updating

  • Change to side-effects
  • Change to warnings or special precautions for use

Updated on 31 March 2009 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

Addition of paragraph:

 

Suicide/suicidal thoughts or clinical worsening:

Depression in bipolar disorder is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.

 

In clinical studies of patients with major depressive episodes in bipolar disorder an increased risk of suicide-related events was observed in young adult patients less than 25 years of age who were treated with quetiapine as compared to those treated with placebo (3.0% vs. 0%, respectively).

 

Section 4.8

Addition of side-effects to table:

 

Blood and lymphatic system disorders

Uncommon: Thrombocytopenia

 

Psychiatric disorders

Common: Abnormal dreams and nightmares

 

Investigations

Uncommon: Platelet count decreased 14

Rare: Elevations in blood creatine phosphokinase 15

 

Addition of footnotes 14 & 15:

  1. Platelets 100 x 109/L on at least one occasion.
  2. Based on clinical trial adverse event reports of blood creatine phosphokinase increase not associated with neuroleptic malignant syndrome.

 

Section 10:

 

Change of date:

11th March 2009

Updated on 19 December 2008 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 19 December 2008 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2:

 

Exipient information

 

Sections 4.1, 4.2, 4.4 & 5.1:

 

New indication: bipolar disorder

 

Section 4.4:

 

Information regarding lactose

 

Section 10:

 

Change of date to 5th December 2008

Updated on 3 December 2008 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 May 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

Section 4.4 - Additional section text:

Severe Neutropenia

Severe neutropenia (neutrophil count <0.5 X 109/L) has been uncommonly reported in Seroquel clinical trials. Most cases of severe neutropenia have occurred within a couple of months of starting therapy with Seroquel.   There was no apparent dose  relationship. During post-marketing experience, resolution of leucopenia and/or neutropenia has followed cessation of therapy with Seroquel. Possible risk factors for neutropenia include pre-existing low white cell count (WBC) and history of drug induced neutropenia.  Quetiapine should be discontinued in patients with a neutrophil count <1.0 X 109/L. Patients should be observed for signs and symptoms of infection and neutrophil counts followed (until they exceed 1.5 X 109/L). (See section 5.1).

Section 4.4

Hyperglycaemia

deletion of the words ¡®in very rare cases¡¯

Section 4.8 - Change to Table ¨C Investigators section

Addition of the text: blood glucose increased to hyperglycaemic levels 7

and to the References after the table ¨C reference 7

Section 5.1 -  additional paragraph to end of section.

In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ¡Ý 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count < 1.5 X 109/L, was 1.72% in patients treated with Seroquel compared to 0.73% in placebo-treated patients.  In all clinical trials (placebo-controlled, open-label, active comparator; patients with a baseline neutrophil count ¡Ý1.5 X 109/L), the incidence of at least one occurrence of neutrophil count <0.5 X 109/L was 0.21% in patients treated with Seroquel and 0% in placebo treated patients and the incidence ¡Ý0.5 - <1.0 X 109/L was 0.75% in patients treated with Seroquel and 0.11% in placebo-treated patients.

Section 10 ¨C New revision date of text

14 February 2008

 

Updated on 28 April 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Severe Neutropenia
Severe neutropenia (neutrophil count <0.5 X 109/L) has been uncommonly reported in Seroquel clinical trials. Most cases of severe neutropenia have occurred within a couple of months of starting therapy with Seroquel.   There was no apparent dose  relationship. During post-marketing experience, resolution of leucopenia and/or neutropenia has followed cessation of therapy with Seroquel. Possible risk factors for neutropenia include pre-existing low white cell count (WBC) and history of drug induced neutropenia.  Quetiapine should be discontinued in patients with a neutrophil count <1.0 X 109/L. Patients should be observed for signs and symptoms of infection and neutrophil counts followed (until they exceed 1.5 X 109/L). (See section 5.1).

Section 4.8 - Change to Table ¨C Investigators section

Change of text: blood glucose increased to hyperglycaemic levels 7

and to the References after the table ¨C reference 7

 

Section 5.1 -  additional paragraph to end of section.

In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ¡Ý 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count < 1.5 X 109/L, was 1.72% in patients treated with Seroquel compared to 0.73% in placebo-treated patients.  In all clinical trials (placebo-controlled, open-label, active comparator; patients with a baseline neutrophil count ¡Ý1.5 X 109/L), the incidence of at least one occurrence of neutrophil count <0.5 X 109/L was 0.21% in patients treated with Seroquel and 0% in placebo treated patients and the incidence ¡Ý0.5 - <1.0 X 109/L was 0.75% in patients treated with Seroquel and 0.11% in placebo-treated patients.

Section 4.8 ¨C New revision date of text

14 February 2008

Updated on 21 April 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 21 April 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.5 - Additional section text:

Severe Neutropenia
Severe neutropenia (neutrophil count <0.5 X 109/L) has been uncommonly reported in Seroquel clinical trials. Most cases of severe neutropenia have occurred within a couple of months of starting therapy with Seroquel.   There was no apparent dose  relationship. During post-marketing experience, resolution of leucopenia and/or neutropenia has followed cessation of therapy with Seroquel. Possible risk factors for neutropenia include pre-existing low white cell count (WBC) and history of drug induced neutropenia.  Quetiapine should be discontinued in patients with a neutrophil count <1.0 X 109/L. Patients should be observed for signs and symptoms of infection and neutrophil counts followed (until they exceed 1.5 X 109/L). (See section 5.1).

Section 4.8 - Change to Table ¨C Investigators section

Change of text: blood glucose increased to hyperglycaemic levels 7

and to the References after the table ¨C reference 7

 

Section 5.1 -  additional paragraph to end of section.

In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ¡Ý 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count < 1.5 X 109/L, was 1.72% in patients treated with Seroquel compared to 0.73% in placebo-treated patients.  In all clinical trials (placebo-controlled, open-label, active comparator; patients with a baseline neutrophil count ¡Ý1.5 X 109/L), the incidence of at least one occurrence of neutrophil count <0.5 X 109/L was 0.21% in patients treated with Seroquel and 0% in placebo treated patients and the incidence ¡Ý0.5 - <1.0 X 109/L was 0.75% in patients treated with Seroquel and 0.11% in placebo-treated patients.

Section 4.8 - New revision date of text

14 February 2008

Updated on 5 November 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8

In the frequency of adverse events table:

Under the heading of Immune system disorders, additionally:

Very rare:    Anaphylactic reaction 7

 

Under the heading of Nervous system disorders, additionally text:

Uncommon:   Seizure 1, restless leg syndrome

 

Under the heading Investigations, addition of text for Uncommon

“(predominantly LDL cholesterol)”

 

Section 4.9

First Paragraph:

Deletion of some text and new additional 2 sentences:

 

Fatal outcome has been reported in clinical trials following an acute overdose at 13.6 grams, and in post-marketing on doses as low as 6 grams of seroquel alone. However, survival has also been reported following acute overdoses of up to 30 grams.

 

New third paragraph:

Patients with pre-existing severe cardiovascular disease may be at increased risk of the effects of overdose. (See section 4,4 Special warnings and precautions for use: Cardiovascular).

 

Section 5.1

Additional text under the heading Mechanism of Action.

 

And new final paragraph under the heading Pharmacodynamic Effects:

The extent to which the N-desalkyl quetiapine metabolite contributes to the pharmacological activity of Seroquel in humans is not known.

 

Section 10

New revision date of text: 19 September 2007

Updated on 22 October 2007 PIL

Reasons for updating

  • Addition of marketing authorisation holder
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 14 August 2007 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

Additional new text in the QT Prolongation Paragraph, sentence 3 now includes: 

 

…when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation. Also caution should be exercised when quetiapine is prescribed with medicines known to increase QTc interval, and concomitant neuroleptics, especially….

 

Section 4.5

Additional new last paragraph:

 

Caution should be exercised when quetiapine is used concomitantly with drugs known to cause electrolyte imbalance or to increase QTc interval.

 

Section 4.8

Additional new paragraph after the table references:

 

Cases of QT prolongation, ventricular arrhythmia, sudden unexplained death, cardiac arrest and torsades de pointes have been reported very rarely with the use of neuroleptics and are considered class effects.

Section 10
New revision date of text: 21 June 2007

Updated on 22 January 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4  Additional new text under the sub heading “QT prolongation” after the first existing paragraph

 

Section 4.8: change in text in table

 

Current text:

Blood and lymphatic system disorders

Very Rare:  Neutropenia 3

New text:

Blood and lymphatic system disorders

Unknown:   Neutropenia 3

 

Additionally in the table at the end

 

Current text:

Investigations

Common:  Weight gain, elevations in serum transaminases (ALT, AST) 4,

New text:

Investigations

Common:   Weight gain, elevations in serum transaminases (ALT, AST) 4,  

                  decreased neutrophil count 8

 

 

In the references under the table.

 Reference (3) Deletion of text “or agranulocytosis”

 

Additional text - new reference -  number (8)

 

 

Section 5.1:  Change of text under section Mechanism of Action”

 

Section 5.1:  Additional new text

In placebo-controlled studies in elderly patients with dementia-related psychosis, the incidence of cerebrovascular adverse events per 100 patient years was not higher in quetiapine-treated patients than in placebo-treated patients.

Section 5.2:  Change of text

 

Section 6.1 – Table of excipients - Change of text.

Lactose Monohydrate:            Ferric Oxide, Red (E172) (25 mg tablets)

 

Section 10:  Change to Revision Date to 21 September 2006

Updated on 19 January 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to marketing authorisation holder

Updated on 31 July 2006 PIL

Reasons for updating

  • Change in co-marketing arrangement

Updated on 20 March 2006 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 November 2005 PIL

Reasons for updating

  • Change to instructions about overdose
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 5 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie